« Return to News | Drug Sponsors

Boehringer Ingelheim creates biosmiliars division

Tuesday, September 27, 2011 01:36 PM

Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market, according to InPharm.

The new venture, which the manufacturer says will be a separate business, is tasked with developing and commercializing Boehringer’s own biosimilars.

“We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines,” explained Wolfram Carius, member of Boehringer’s board of managing directors.

“We feel confident that we are able to leverage our capabilities in product development, supply and clinical expertise at Boehringer Ingelheim to offer high quality biosimilars understanding patients’ needs,” he added.

Biosimilars differ from generics in that they are close copies of, rather than identical to, off-patent biologic brands.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.